China's biotech sector is producing globally competitive assets, drawing significant interest from major pharmaceutical companies. China's globalization ambitions also create new engagement opportunities for multinational pharmaceutical and life science companies.
Von Experts Table.Briefings
China's NEV market is under strain as aggressive price cuts and questionable sales tactics trigger regulatory attention. As automakers scramble to maintain growth in a slowing economy, the government faces mounting pressure to strike a balance between industry discipline and demand stimulation.
Von Experts Table.Briefings
With strong government backing, significant capital is pouring into the humanoid robotics sector in China. Market activity is robust, with investment volumes already surpassing the total recorded in all of 2024.
Von Experts Table.Briefings
The trade war is changing global supply chains. A new survey reveals that companies are relocating production away from the U.S. and China. Europe is the focus here.
Von Experts Table.Briefings
Chinese EV makers are under pressure in Europe as demand weakens and tariffs take effect. Market shares and registrations fell in the first quarter. Only BYD is bucking the trend.
Von Experts Table.Briefings
Despite the US tariffs, Chinese exports far exceeded the Reuters poll estimate. Growth was fueled by a sharp increase in shipments to Southeast Asia, which helped offset a steep drop in exports to the United States.
Von Experts Table.Briefings
Domestic tourism in China finally returned to pre-pandemic levels in 2024. This year’s Labor Day holiday is set to give the sector another boost.
Von
In recent years, China's data transfer restrictions have forced many multinationals to store data locally. However, free trade zones (FTZs) are now experimenting with more flexible approaches. Still, certain key industries continue to face significant constraints.
Von Experts Table.Briefings
A new Section 232 probe targets semiconductor imports, raising tariff risks for major chip-producing countries. Previously exempt from Trump’s reciprocal tariffs, the sector now faces potential duties of 25 percent or more — possibly within weeks.
Von Experts Table.Briefings
China’s biopharma industry is experiencing a commercial breakthrough. Driven by robust government policies and rapidly growing global licensing deals, Chinese innovative drugs are no longer just following global trends—they’re setting them.
Von
